FRANKFURT/LONDON (Reuters) -- AstraZeneca's COVID-19 vaccine developed with Oxford University was 79% effective in preventing symptomatic illness in a large trial in Chile, Peru and the United States, the company said on Monday, paving the way for it to apply for U.S. approval.
The vaccine was also 100% effective against severe or critical disease and hospitalization, and was safe, the partners said on Monday, releasing results of the late-stage human trial study of more than 32,000 volunteers across all age groups.
